Design of cyclic and linear peptide antagonists of vasopressin and oxytocin: current status and future directions
- 29 April 1993
- journal article
- Published by Elsevier BV in Regulatory Peptides
- Vol. 45 (1-2), 279-283
- https://doi.org/10.1016/0167-0115(93)90220-3
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Receptor‐Specific Antagonists of Vasopressin and OxytocinAnnals of the New York Academy of Sciences, 1993
- Development and pharmacological assessment of novel peptide and nonpeptide oxytocin antagonistsRegulatory Peptides, 1993
- Oxytocin antagonists and their therapeutic useRegulatory Peptides, 1993
- Design, Synthesis and Some uses of Receptor-Specific Agonists and Antagonists of Vasopressin and OxytocinJournal of Receptor Research, 1993
- Radioligand binding studies reveal marked species differences in the vasopressin V1 receptor of rat, rhesus and human tissuesLife Sciences, 1992
- A POTENT NEW SYNTHETIC ANALOG OF VASOPRESSIN WITH RELATIVE AGONIST SPECIFICITY FOR THE PITUITARYEndocrinology, 1991
- Labelling of vasopressin and oxytocin receptors from the human uterusEuropean Journal of Pharmacology, 1990
- Solid-phase synthesis of 16 potent (selective and nonselective) in vivo antagonists of oxytocinJournal of Medicinal Chemistry, 1989
- [125I]-[d(CH2)5, Sar7] AVP: A Selective Radioligand for V1Vasopressin ReceptorsJournal of Receptor Research, 1989
- Effects of a specific inhibitor of the vascular action of vasopressin in humans.Hypertension, 1984